Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 271

1.

Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages.

Bayik D, Tross D, Klinman DM.

Front Immunol. 2018 Mar 26;9:608. doi: 10.3389/fimmu.2018.00608. eCollection 2018.

2.

Regulation of the maturation of human monocytes into immunosuppressive macrophages.

Bayik D, Tross D, Haile LA, Verthelyi D, Klinman DM.

Blood Adv. 2017 Dec 4;1(26):2510-2519. doi: 10.1182/bloodadvances.2017011221. eCollection 2017 Dec 12.

3.

Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.

Nie Y, He J, Shirota H, Trivett AL, Yang, Klinman DM, Oppenheim JJ, Chen X.

Sci Signal. 2018 Jan 2;11(511). pii: eaan0790. doi: 10.1126/scisignal.aan0790.

PMID:
29295954
4.

Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy.

Zhu G, Lynn GM, Jacobson O, Chen K, Liu Y, Zhang H, Ma Y, Zhang F, Tian R, Ni Q, Cheng S, Wang Z, Lu N, Yung BC, Wang Z, Lang L, Fu X, Jin A, Weiss ID, Vishwasrao H, Niu G, Shroff H, Klinman DM, Seder RA, Chen X.

Nat Commun. 2017 Dec 5;8(1):1954. doi: 10.1038/s41467-017-02191-y.

5.

Effect of Calcium Carbonate Encapsulation on the Activity of Orally Administered CpG Oligonucleotides.

Kayraklioglu N, Scheiermann J, Alvord WG, Klinman DM.

Mol Ther Nucleic Acids. 2017 Sep 15;8:243-249. doi: 10.1016/j.omtn.2017.06.015. Epub 2017 Jun 23.

6.

Three distinct pneumotypes characterize the microbiome of the lung in BALB/cJ mice.

Scheiermann J, Klinman DM.

PLoS One. 2017 Jul 6;12(7):e0180561. doi: 10.1371/journal.pone.0180561. eCollection 2017.

7.

A comprehensive evaluation for the treatment of lupus nephritis.

Zampeli E, Klinman DM, Gershwin ME, Moutsopoulos HM.

J Autoimmun. 2017 Mar;78:1-10. doi: 10.1016/j.jaut.2016.12.011. Epub 2017 Jan 9. Review.

PMID:
28082046
8.

Shedding New Light on the Process of "Licensing" for Pathogenicity by Th Lymphocytes.

Tan C, Wandu WS, Lee RS, Hinshaw SH, Klinman DM, Wawrousek E, Gery I.

J Immunol. 2017 Jan 15;198(2):681-690. doi: 10.4049/jimmunol.1502108. Epub 2016 Dec 16.

9.

IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity.

Shirota H, Klinman DM, Ito SE, Ito H, Kubo M, Ishioka C.

Cancer Immunol Res. 2017 Jan;5(1):61-71. doi: 10.1158/2326-6066.CIR-16-0113. Epub 2016 Dec 5.

10.
11.

Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides.

Bayik D, Gursel I, Klinman DM.

Pharmacol Res. 2016 Mar;105:216-25. doi: 10.1016/j.phrs.2015.11.010. Epub 2016 Jan 15. Review.

PMID:
26779666
12.

Use of nanoparticles to deliver immunomodulatory oligonucleotides.

Klinman DM, Sato T, Shimosato T.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Jul;8(4):631-7. doi: 10.1002/wnan.1382. Epub 2015 Dec 12. Review.

13.

IRF5 and IRF8 modulate the CAL-1 human plasmacytoid dendritic cell line response following TLR9 ligation.

Steinhagen F, Rodriguez LG, Tross D, Tewary P, Bode C, Klinman DM.

Eur J Immunol. 2016 Mar;46(3):647-55. doi: 10.1002/eji.201545911. Epub 2015 Dec 17.

14.

Synthetic Oligodeoxynucleotides Containing Multiple Telemeric TTAGGG Motifs Suppress Inflammasome Activity in Macrophages Subjected to Oxygen and Glucose Deprivation and Reduce Ischemic Brain Injury in Stroke-Prone Spontaneously Hypertensive Rats.

Zhao J, Mou Y, Bernstock JD, Klimanis D, Wang S, Spatz M, Maric D, Johnson K, Klinman DM, Li X, Li X, Hallenbeck JM.

PLoS One. 2015 Oct 16;10(10):e0140772. doi: 10.1371/journal.pone.0140772. eCollection 2015.

15.

CpG Oligonucleotides as Cancer Vaccine Adjuvants.

Shirota H, Tross D, Klinman DM.

Vaccines (Basel). 2015 May 8;3(2):390-407. doi: 10.3390/vaccines3020390. Review.

16.

Intrapulmonary Delivery of CpG Microparticles Eliminates Lung Tumors.

Sato T, Shimosato T, Ueda A, Ishigatsubo Y, Klinman DM.

Mol Cancer Ther. 2015 Oct;14(10):2198-205. doi: 10.1158/1535-7163.MCT-15-0401. Epub 2015 Jul 23.

17.

Leucine-Rich Repeat Kinase 2 (Lrrk2) Deficiency Diminishes the Development of Experimental Autoimmune Uveitis (EAU) and the Adaptive Immune Response.

Wandu WS, Tan C, Ogbeifun O, Vistica BP, Shi G, Hinshaw SJ, Xie C, Chen X, Klinman DM, Cai H, Gery I.

PLoS One. 2015 Jun 11;10(6):e0128906. doi: 10.1371/journal.pone.0128906. eCollection 2015.

18.

Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells.

Wang J, Shirota Y, Bayik D, Shirota H, Tross D, Gulley JL, Wood LV, Berzofsky JA, Klinman DM.

J Immunol. 2015 May 1;194(9):4215-21. doi: 10.4049/jimmunol.1402004. Epub 2015 Mar 30.

19.

Therapeutic implications of orally delivered immunomodulatory oligonucleotides.

Klinman DM.

Mol Ther. 2015 Feb;23(2):222-3. doi: 10.1038/mt.2014.251. No abstract available.

20.

Suppressive oligodeoxynucleotides promote the generation of regulatory T cells by inhibiting STAT1 phosphorylation.

Bode C, Wang J, Klinman DM.

Int Immunopharmacol. 2014 Dec;23(2):516-22. doi: 10.1016/j.intimp.2014.09.027. Epub 2014 Oct 12.

21.

Apoptosis of antigen-specific CTLs contributes to low immune response in gut-associated lymphoid tissue post vaccination.

Shimada M, Yoshizaki S, Ichino M, Klinman DM, Okuda K.

Vaccine. 2014 Sep 8;32(40):5198-205. doi: 10.1016/j.vaccine.2014.07.046. Epub 2014 Jul 25.

PMID:
25066739
22.

Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors.

Zhao BG, Vasilakos JP, Tross D, Smirnov D, Klinman DM.

J Immunother Cancer. 2014 May 13;2:12. doi: 10.1186/2051-1426-2-12. eCollection 2014.

23.

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.

Scheiermann J, Klinman DM.

Vaccine. 2014 Nov 12;32(48):6377-89. doi: 10.1016/j.vaccine.2014.06.065. Epub 2014 Jun 24. Review.

24.

TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens.

Shirota H, Klinman DM.

Methods Mol Biol. 2014;1139:337-44. doi: 10.1007/978-1-4939-0345-0_27.

PMID:
24619691
25.

IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice.

Hodge DL, Berthet C, Coppola V, Kastenmüller W, Buschman MD, Schaughency PM, Shirota H, Scarzello AJ, Subleski JJ, Anver MR, Ortaldo JR, Lin F, Reynolds DA, Sanford ME, Kaldis P, Tessarollo L, Klinman DM, Young HA.

J Autoimmun. 2014 Sep;53:33-45. doi: 10.1016/j.jaut.2014.02.003. Epub 2014 Feb 28.

26.

Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis.

Bode C, Kinjo T, Alvord WG, Klinman DM.

Carcinogenesis. 2014 May;35(5):1078-83. doi: 10.1093/carcin/bgu005. Epub 2014 Jan 8.

27.

Recent progress concerning CpG DNA and its use as a vaccine adjuvant.

Shirota H, Klinman DM.

Expert Rev Vaccines. 2014 Feb;13(2):299-312. doi: 10.1586/14760584.2014.863715. Epub 2013 Nov 26. Review.

PMID:
24308579
28.

Plasmacytoid dendritic cell response to CpG ODN correlates with CXCL16 expression and is inhibited by ox-LDL.

Gursel M, Klinman DM, Gursel I.

Mediators Inflamm. 2013;2013:312590. doi: 10.1155/2013/312590. Epub 2013 Nov 4.

29.

Synthetic oligodeoxynucleotides containing suppressive TTAGGG motifs inhibit AIM2 inflammasome activation.

Kaminski JJ, Schattgen SA, Tzeng TC, Bode C, Klinman DM, Fitzgerald KA.

J Immunol. 2013 Oct 1;191(7):3876-83. doi: 10.4049/jimmunol.1300530. Epub 2013 Aug 28.

30.

Use of CpG oligonucleotides for cancer immunotherapy and their effect on immunity in the tumor microenvironment.

Shirota H, Klinman DM.

Immunotherapy. 2013 Aug;5(8):787-9. doi: 10.2217/imt.13.70. No abstract available.

PMID:
23902544
31.

Suppressive oligodeoxynucleotides promote the development of Th17 cells.

Bode C, Yang XP, Kiu H, Klinman DM.

PLoS One. 2013 Jul 2;8(7):e67991. doi: 10.1371/journal.pone.0067991. Print 2013.

32.

β-Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-α production by human plasmacytoid dendritic cells, and promote inflammation.

Tewary P, de la Rosa G, Sharma N, Rodriguez LG, Tarasov SG, Howard OM, Shirota H, Steinhagen F, Klinman DM, Yang D, Oppenheim JJ.

J Immunol. 2013 Jul 15;191(2):865-74. doi: 10.4049/jimmunol.1201648. Epub 2013 Jun 17.

33.

Differential involvement of Th1 and Th17 in pathogenic autoimmune processes triggered by different TLR ligands.

Shi G, Vistica BP, Nugent LF, Tan C, Wawrousek EF, Klinman DM, Gery I.

J Immunol. 2013 Jul 1;191(1):415-23. doi: 10.4049/jimmunol.1201732. Epub 2013 May 29.

34.

IRF-5 and NF-κB p50 co-regulate IFN-β and IL-6 expression in TLR9-stimulated human plasmacytoid dendritic cells.

Steinhagen F, McFarland AP, Rodriguez LG, Tewary P, Jarret A, Savan R, Klinman DM.

Eur J Immunol. 2013 Jul;43(7):1896-906. doi: 10.1002/eji.201242792. Epub 2013 May 28.

35.

Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein.

Shimada M, Abe S, Takahashi T, Shiozaki K, Okuda M, Mizukami H, Klinman DM, Ozawa K, Okuda K.

PLoS One. 2013;8(3):e57606. doi: 10.1371/journal.pone.0057606. Epub 2013 Mar 28.

36.

Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2.

Kobayashi N, Hong C, Klinman DM, Shirota H.

J Immunol. 2013 Feb 15;190(4):1882-9. doi: 10.4049/jimmunol.1201063. Epub 2013 Jan 7.

37.

Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells.

Takahashi R, Sato T, Klinman DM, Shimosato T, Kaneko T, Ishigatsubo Y.

Int J Oncol. 2013 Feb;42(2):429-36. doi: 10.3892/ijo.2012.1755. Epub 2012 Dec 28.

38.

Effect of CpG ODN on monocytic myeloid derived suppressor cells.

Shirota H, Klinman DM.

Oncoimmunology. 2012 Aug 1;1(5):780-782.

39.

Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection.

Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters RC, Kirk J, Eppler B, Klinman DM, Sui Y, Gagnon S, Belyakov IM, Mumper RJ, Berzofsky JA.

Nat Med. 2012 Aug;18(8):1291-6. doi: 10.1038/nm.2866. Epub 2012 Jul 15.

40.

Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.

Steinhagen F, Meyer C, Tross D, Gursel M, Maeda T, Klaschik S, Klinman DM.

J Leukoc Biol. 2012 Oct;92(4):775-85. doi: 10.1189/jlb.1011522. Epub 2012 Jul 2.

41.

The counter regulatory response induced by CpG oligonucleotides prevents bleomycin induced pneumopathy.

Kinjo T, Tomaru K, Haines DC, Klinman DM.

Respir Res. 2012 Jun 18;13:47. doi: 10.1186/1465-9921-13-47.

42.

Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells.

Shirota Y, Shirota H, Klinman DM.

J Immunol. 2012 Feb 15;188(4):1592-9. doi: 10.4049/jimmunol.1101304. Epub 2012 Jan 9.

43.

CpG DNA as a vaccine adjuvant.

Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM.

Expert Rev Vaccines. 2011 Apr;10(4):499-511. doi: 10.1586/erv.10.174. Review.

44.

The acceleration of wound healing in primates by the local administration of immunostimulatory CpG oligonucleotides.

Yamamoto M, Sato T, Beren J, Verthelyi D, Klinman DM.

Biomaterials. 2011 Jun;32(18):4238-42. doi: 10.1016/j.biomaterials.2011.02.043. Epub 2011 Mar 21.

45.

Effect of suppressive oligodeoxynucleotides on the development of inflammation-induced papillomas.

Ikeuchi H, Kinjo T, Klinman DM.

Cancer Prev Res (Phila). 2011 May;4(5):752-7. doi: 10.1158/1940-6207.CAPR-10-0290. Epub 2011 Mar 2.

46.

CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity.

Shirota H, Klinman DM.

Cancer Immunol Immunother. 2011 May;60(5):659-69. doi: 10.1007/s00262-011-0973-y. Epub 2011 Feb 4.

PMID:
21318638
47.

A novel role for IL-22R1 as a driver of inflammation.

Savan R, McFarland AP, Reynolds DA, Feigenbaum L, Ramakrishnan K, Karwan M, Shirota H, Klinman DM, Dunleavy K, Pittaluga S, Anderson SK, Donnelly RP, Wilson WH, Young HA.

Blood. 2011 Jan 13;117(2):575-84. doi: 10.1182/blood-2010-05-285908. Epub 2010 Oct 22.

48.

Accelerated wound healing mediated by activation of Toll-like receptor 9.

Sato T, Yamamoto M, Shimosato T, Klinman DM.

Wound Repair Regen. 2010 Nov-Dec;18(6):586-93. doi: 10.1111/j.1524-475X.2010.00632.x. Epub 2010 Oct 13.

49.

TLR-based immune adjuvants.

Steinhagen F, Kinjo T, Bode C, Klinman DM.

Vaccine. 2011 Apr 12;29(17):3341-55. doi: 10.1016/j.vaccine.2010.08.002. Epub 2010 Aug 14. Review.

50.

Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.

Klinman DM, Klaschik S, Tomaru K, Shirota H, Tross D, Ikeuchi H.

Vaccine. 2010 Feb 23;28(8):1919-23. doi: 10.1016/j.vaccine.2009.10.094.

Supplemental Content

Loading ...
Support Center